Navigation Links
FDA Panel to Consider Brain Stimulator for Epilepsy
Date:2/21/2013

By Barbara Bronson Gray
HealthDay Reporter

THURSDAY, Feb. 21 (HealthDay News) - A U.S. Food and Drug Administration advisory panel will weigh on Friday the merits of a new therapy for some people with epilepsy who have seizures that don't respond to medication.

Smaller and thinner than an implantable defibrillator, the battery-powered, programmable device, called the RNS System, is placed just under the skull during surgery. Electrodes reach from the device to the one or two places in the patient's brain that create the abnormal electrical activity that causes seizures. The device works by short-circuiting nerve cells in that area to normalize brain activity before a seizure is triggered.

"This is the first responsive neuro-stimulation system ever designed," said Frank Fischer, president and CEO of Mountain View Calif.-based NeuroPace Inc., which developed the device. "Our long-term results show that patients have a reduction of 50 percent or more in their seizure frequency, compared to baseline, and a lessening of seizure severity."

The device is designed specifically for people aged 18 and older with partial-onset epilepsy, which occurs when one or more fixed locations in a person's brain start the cascade of nerve firing that creates a seizure.

NeuroPace has done two studies involving a total of 256 patients who were monitored for a period of between two and nine years, without any significant problems, according to Fischer.

Epilepsy is a brain disorder in which a person suffers repeated seizures over time.

It affects more than 2 million Americans, according to the Epilepsy Foundation, making it the third most common neurological disorder in the United States, after Alzheimer's and stroke. Seizures are episodes of disturbed brain activity that cause changes in attention or behavior. Brain cells keep firing instead of acting in an organized way. The malfunctioning electrical system of t
'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Independent panel to present findings on diagnosing gestational diabetes mellitus
2. Perampanel for epilepsy: No proof of added benefit
3. FDA Panel Votes for Tougher Curbs on Vicodin, Other Painkillers
4. FDA Panel Weighs Tougher Restrictions on Some Prescription Painkillers
5. Panel recommends changing name of common disorder in women
6. 28W [ZT-P3060-28EAE] LED Panel is Announced by Zhongtian Lighting
7. Attempts to correct death panel myth may backfire
8. 18W Normal Ultra Slim Series Panel Light [ZT-P3030-18EAH] from Zhongtian Lighting
9. AxoGen, Inc. to sponsor Educational Symposium and Panel Discussion at 2013 Annual Meetings of American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery
10. LED Panel Light [ZT-P3012-58EAC] is Released by Zhongtian Lighting
11. A New Dimmable 30W Panel Light from Zhongtian Lighting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel to Consider Brain Stimulator for Epilepsy
(Date:11/27/2014)... (PRWEB) November 27, 2014 Now that ... season has officially launched, Emassagechair.com has announced ... Monday Discount Event. , Negotiating on behalf of ... top massage chair brands, Emassagechair.com has generated significant buzz ... deals and biggest discounts yet. , Shoppers are excited ...
(Date:11/27/2014)... 27, 2014 VogueQueen.com is making every ... ladies across the world. As the premier online supplier ... is proud to release a huge selection of sexy ... outfits, it is also providing many beautiful styles in ... gowns at discounted prices. , “VogueQueen.com hopes to ...
(Date:11/27/2014)... 27, 2014 Developers and plugin specialist of ... entitled ProPip, taking FCPX to the next level. , “ProPip ... a few clicks of a mouse,” said Christina Austin, CEO ... our users will appreciate.” , With ProPip users can show ... possibilities truly endless. ProPip is great for commentaries, news casting, ...
(Date:11/27/2014)... HealthPostures, a leading national designer ... announced that it has entered into a new ... will put HealthPostures' products into central Indiana’s premiere ... to having its products sold through Commercial Office ... with the business decision makers in the Indianapolis ...
(Date:11/27/2014)... At The Little Gym, we know ... as no surprise when a recent study confirmed that ... The Journal of Pediatrics found that “Promoting ... during the school years may be important not only ... study monitored two groups of children; those that were ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... have, for the first time, taken adult stem cells and ... human jaw.They say the groundbreaking work may one day //lead ... suffer from temporomandibular disorders. ,The study started with ... these cells can be coaxed to become any other type ...
... the last half century, and officials at the ... be diagnosed with it this year.,The study, which analyzed ... ages of 30 and 50,// found what the researchers ... tanning can be dangerous to healthy skin. ,Melanoma ...
... and observational studies previously conducted in elderly populations ... were performed before intracoronary stents and use of ... Dr. Hanoch Hod, of Chaim Sheba Medical //Center ... consecutive patients aged 70 or older treated for ...
... hormone may help patients in treating a rare disorder ... metabolic abnormalities.The study's author found that the results of ... role of leptin in common metabolic conditions such as ... her colleagues found that a lab-engineered version of leptin, ...
... control to limit women's periods ,Seasonale, a new drug ... reduce the number of women's periods to four a year ... pills, but for longer spans of time.// ,Seasonale ... ,"For women who desire prevention of pregnancy and are comfortable ...
... milk chocolate, which is most commonly used in candy ... They found the same discouraging result among patients who ... suggest that milk and other dairy products somehow discourage ... chocolate. Only subjects who ate dark chocolate showed a ...
Cached Medicine News:Health News:Solarium use is associated with an increased risk of skin cancer 2Health News:Angioplasty plus stenting better than thrombolysis for elderly patients with AMI, 2Health News:Obesity Hormone -' Leptin' may treat Metabolic Disorder 2Health News:New birth control to limit women's periods 2Health News:When it comes to health, all chocolates not the same. 2
(Date:11/26/2014)... 2014  Array BioPharma Inc. (Nasdaq: ... Chief Executive Officer, Ron Squarer , ... The public is welcome to participate in ... BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray 2014 ... Time Location: Palace Hotel, New York CityEvent:Oppenheimer ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen ... AZN ) today announced that AMAGINE-2 TM , a pivotal, ... more than 1,800 patients with moderate-to-severe plaque psoriasis, met its ... and placebo at week 12. Brodalumab 210 mg given every ... shown to be superior to Stelara on the primary endpoint ...
(Date:11/26/2014)... and HERZLIYA PITUACH, Israel, Nov. 25, 2014 ... Company"), a clinical stage biopharmaceutical company that engages ... for the treatment of inflammatory diseases and cancer, ... underwritten public offering of 3,450,000 units, with each ... common stock, par value $0.0001 per share, and ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... OSLO, Norway, October 31, 2011 Oslo ... oncology. The true strength of the Norwegian cluster lies ... than the ones available to cancer patients today. ... cluster within the field of oncology, dedicated to accelerating ...
... Inc. (ARKRAY) announced today that the GLUCOCARD® Vital and ... (DoD) Uniform Formulary.  The DoD Pharmacy and Therapeutic committee ... 01 Blood Glucose Meters as the first and second ... of service as noted by the Uniform Formulary Beneficiary ...
Cached Medicine Technology:Expanding Norwegian Cluster of Excellence Dedicated to Oncology 2Expanding Norwegian Cluster of Excellence Dedicated to Oncology 3ARKRAY's GLUCOCARD® Vital and 01 Blood Glucose Meters are now on the Department of Defense Uniform Formulary. 2
This radiolucent One-piece fixator permits independent mechanical adjustments of the following: Distraction/Compression, Dorsal/Palmar Translation, Radial/Ulnar Translation, Flexion/Extension....
Provides basic reduction capabilities for angulation, rotation and length. Ball joint design offers fracture reduction in all planes....
The Medium External Fixator has a medium Combination Clamp that connects rod to rod or pin to rod as well as a Medium Multi-Pin Clamp that connects pins to rods allowing parallel pin placement....
... the Pennig Minifixator, combines the advantage of secure ... tissue dissection is not necessary, since in general, ... fixation in the hand has required bridging of ... (Asche and Burny) because of the design of ...
Medicine Products: